ARCHIVES

Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

IOM Review Of Duke Genomics Trials To Focus On Validation, Scientific Criteria

October 22, 2010

Clinical Trials Approved By NCI

January 30, 2004

Varmus Projects FY2011 As “Particularly Tight”

November 12, 2010

Indiana to Close Proton Beam Facility Amid Nationwide Building Boom

October 17, 2014

Cancer Program Advocate Mary Lasker, 93, Prodded Government, Scientists For Cures

March 4, 1994

DCT Board Okays $3 Million In New Programs, $8 Million In Recompetitions

October 24, 1980